PMID- 21645519
OWN - NLM
STAT- MEDLINE
DCOM- 20120106
LR  - 20211020
IS  - 1095-8584 (Electronic)
IS  - 0022-2828 (Print)
IS  - 0022-2828 (Linking)
VI  - 51
IP  - 4
DP  - 2011 Oct
TI  - Pharmacologic and genetic strategies to enhance cell therapy for cardiac 
      regeneration.
PG  - 619-25
LID - 10.1016/j.yjmcc.2011.05.015 [doi]
AB  - Cell-based therapy is emerging as an exciting potential therapeutic approach for 
      cardiac regeneration following myocardial infarction (MI). As heart failure (HF) 
      prevalence increases over time, development of new interventions designed to aid 
      cardiac recovery from injury are crucial and should be considered more broadly. 
      In this regard, substantial efforts to enhance the efficacy and safety of cell 
      therapy are continuously growing along several fronts, including modifications to 
      improve the reprogramming efficiency of inducible pluripotent stem cells (iPS), 
      genetic engineering of adult stem cells, and administration of growth factors or 
      small molecules to activate regenerative pathways in the injured heart. These 
      interventions are emerging as potential therapeutic alternatives and/or adjuncts 
      based on their potential to promote stem cell homing, proliferation, 
      differentiation, and/or survival. Given the promise of therapeutic interventions 
      to enhance the regenerative capacity of multipotent stem cells as well as 
      specifically guide endogenous or exogenous stem cells into a cardiac lineage, 
      their application in cardiac regenerative medicine should be the focus of future 
      clinical research. This article is part of a special issue entitled "Key 
      Signaling Molecules in Hypertrophy and Heart Failure."
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Kanashiro-Takeuchi, Rosemeire M
AU  - Kanashiro-Takeuchi RM
AD  - Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
      Medicine, Miami, FL, USA.
FAU - Schulman, Ivonne Hernandez
AU  - Schulman IH
FAU - Hare, Joshua M
AU  - Hare JM
LA  - eng
GR  - R01 HL107110/HL/NHLBI NIH HHS/United States
GR  - R01 HL084275/HL/NHLBI NIH HHS/United States
GR  - R01 HL094849/HL/NHLBI NIH HHS/United States
GR  - U54 HL081028/HL/NHLBI NIH HHS/United States
GR  - P20 HL101443/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20110530
PL  - England
TA  - J Mol Cell Cardiol
JT  - Journal of molecular and cellular cardiology
JID - 0262322
RN  - 11096-26-7 (Erythropoietin)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Erythropoietin/pharmacology/therapeutic use
MH  - Genetic Engineering
MH  - Genetic Therapy
MH  - Granulocyte Colony-Stimulating Factor/pharmacology/therapeutic use
MH  - Heart/*physiopathology
MH  - Heart Failure/physiopathology/*therapy
MH  - Humans
MH  - *Regeneration
MH  - *Stem Cell Transplantation
MH  - Stem Cells/metabolism
PMC - PMC3408226
MID - NIHMS300899
COIS- Disclosures All the authors declared no conflict of interest that could influence 
      this work.
EDAT- 2011/06/08 06:00
MHDA- 2012/01/10 06:00
PMCR- 2012/10/01
CRDT- 2011/06/08 06:00
PHST- 2011/03/15 00:00 [received]
PHST- 2011/05/18 00:00 [revised]
PHST- 2011/05/20 00:00 [accepted]
PHST- 2011/06/08 06:00 [entrez]
PHST- 2011/06/08 06:00 [pubmed]
PHST- 2012/01/10 06:00 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - S0022-2828(11)00216-1 [pii]
AID - 10.1016/j.yjmcc.2011.05.015 [doi]
PST - ppublish
SO  - J Mol Cell Cardiol. 2011 Oct;51(4):619-25. doi: 10.1016/j.yjmcc.2011.05.015. Epub 
      2011 May 30.